United States v. Cancer Treatment Centers of America

350 F. Supp. 2d 765, 22 I.E.R. Cas. (BNA) 202, 2004 U.S. Dist. LEXIS 22974, 2004 WL 2584712
CourtDistrict Court, N.D. Illinois
DecidedNovember 10, 2004
Docket99 C 8287
StatusPublished
Cited by6 cases

This text of 350 F. Supp. 2d 765 (United States v. Cancer Treatment Centers of America) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Cancer Treatment Centers of America, 350 F. Supp. 2d 765, 22 I.E.R. Cas. (BNA) 202, 2004 U.S. Dist. LEXIS 22974, 2004 WL 2584712 (N.D. Ill. 2004).

Opinion

MEMORANDUM OPINION AND ORDER

MORAN, Senior District Judge.

Plaintiff-relator Jacqueline Grandbau (relator) brought this qui tam action on behalf of the governments of the United States and the State of Illinois, and alleges that defendant Cancer Treatment Centers of America (CTCA) engaged in fraudulent billing practices in violation of the False Claims Act,'31 U.S.C. §§ 3729-3733(FCA). Defendant Midwest Regional Medical Center (MRMC), a subsidiary of CTCA, filed a counterclaim against relator in which it claims relator is liable for breach of fiduciary duty, breach of a confidentiality agreement and conversion. These claims arise from relator’s response to a subpoena issued by the government during its investigation of suspected healthcare fraud committed by defendant. Relator filed a motion to dismiss defendant’s counterclaims on statutory and policy grounds, and the government has supported that motion by way of an amicus curiae submission. For the following reasons, relator’s motion is granted in part and denied in part.

BACKGROUND

For purposes of this order the factual background is taken from defendant’s counterclaim. MRMC operates a hospital in Zion, Illinois, and in 1997 it hired relator to serve as a Quality Assurance Coordinator. In that role, relator’s responsibilities included medical coding, which involves working with billing documents and assigning the proper medical treatment codes to the services that patients actually received. In carrying out her medical coding duties, relator was privy to confidential documents, and in a confidentiality agreement she agreed not to disclose proprietary or confidential information “for any reason or purpose whatsoever.” Relator’s access to confidential documents increased when she was promoted in November 1998.

In or around early March 1999, relator received a subpoena issued by the United States Department of Justice (DOJ). The subpoena was mailed to her at defendant’s business, addressed to her as “QA Coordinator, PCI,” and requested production of documents necessary for the DOJ’s investigation of federal health care offenses, such as “Medical records and billing records relating to suspected billing discrepancies, including excessive charges and improper billing.” Defendant claims that relator never told any supervisor, director, officer or coworker that she received the subpoena. Neither did she disclose to anyone at MRMC that she had collected, copied and delivered to the government numerous documents containing confidential information. Defendant further alleges that relator collected and .produced to the government numerous confidential and *769 proprietary documents that were outside the scope of the subpoena.

On December 20, 1999, relator filed a qui tam action, which remained under seal pursuant to the FCA. After reviewing the action, the government declined to intervene on March 13, 2002, and immediately thereafter Judge Aspen ordered the complaint be unsealed and served on defendant. Defendant filed its counterclaim on March 7, 2003, and relator moved to dismiss the counterclaim on April 30, 2003. On April 2, 2004, the government, as ami-cus curiae, filed a memorandum in support of relator’s motion to dismiss.

Defendant’s counterclaim contains three counts. First, defendant alleges that relator breached her fiduciary duty by failing to disclose her receipt of and response to the subpoena. Defendant claims that relator’s breach provided grounds for her termination and that it also led to the substantial sums it spent in the defense of the qui tam action. Second, defendant claims that by secretly responding to the subpoena, relator breached the confidentiality agreement. As in Count I, 'defendant claims that relator could have been fired for her breach of the confidentiality agreement, and that her breach led to substantial litigation- expenses. Lastly, defendant asserts that the subpoena was addressed to relator in her official capacity and that by secretly responding to it she converted the subpoena for her own benefit. For this final count, defendant seeks the same relief that it requests in Counts I and II.

In her motion to dismiss, relator insists that defendant has brought its counterclaim in retaliation for her qui tam action, and that allowing the counterclaim to proceed is contrary to the FCA’s policy of encouraging qui tam actions and would chill future whistleblowers from shedding light on wrongdoings. The government asserts that policy interests, specifically those promoting truthful responses to subpoenas and protecting whistleblowers from retaliation, render the confidentiality agreement unenforceable. Relator also asserts that defendant fails to state a claim for conversion because subpoena is not property that is subject to conversion.

DISCUSSION

In deciding a motion to dismiss brought under Federal Rule of Civil Procedure 12(b)(6), we assume the truth of all well-pleaded allegations, making all inferences in the nonmovant’s favor. Sidney S. Arst Co. v. Pipefitters Welfare Educ. Fund, 25 F.3d 417, 420 (7th Cir.1994). The court should dismiss a claim only if it appears that the nonmovant can prove no set of facts in support of its claim that would entitle it to relief. Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957). Complaints need not detail the specific facts involved in a claim and may plead conclusions. Higgs v. Carver, 286 F.3d 437, 439 (7th Cir.2002).

Prior to reaching defendant’s counts, we must discuss several issues raised by relator and the government. The most important and complicated matter is the relationship between defendant’s counterclaim and the FCA. We recognize the importance of the FCA, the purpose of which is to “enhance the Government’s ability to recover losses sustained as a result of fraud against the Government.” S. Rep. 99-345, at 1, U.S.Code Cong. & Admin.News 1986, 5266. Achieving that goal requires the “coordinated effort” between private citizens and the government. Id. at 2, U.S.Code Cong. & Admin.News 1986, 5266, 5266-67. From targeting massive contractor fraud during the Civil War to halting healthcare fraud today, the ability of individuals to serve as private attorneys general and to protect the interests *770 of the government has and continues to serve vital purposes.

Relator and the government focus on these policy concerns when they forcefully contend that defendant’s counterclaims would chill future whistleblowers. In making that argument, relator and the government fail to distinguish relator’s response to the subpoena from her filing of the qui tam action. Defendant could bring its counterclaim independent of relator’s qui tam action and relator could have filed the qui tam action even if she disclosed the subpoena and made no attempt to respond to it.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gialamas v. Deacon
2023 IL App (1st) 221400-U (Appellate Court of Illinois, 2023)
State ex rel. Rogers v. Bancorp Bank
Superior Court of Delaware, 2023
United States ex rel. Ceas v. Chrysler Group LLC
191 F. Supp. 3d 885 (N.D. Illinois, 2016)
United States ex rel. Ruhe v. Masimo Corp.
929 F. Supp. 2d 1033 (C.D. California, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
350 F. Supp. 2d 765, 22 I.E.R. Cas. (BNA) 202, 2004 U.S. Dist. LEXIS 22974, 2004 WL 2584712, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-cancer-treatment-centers-of-america-ilnd-2004.